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Abstract
Purpose The aim of this study is to compare the analgesic
efficacy and tolerability of a pre-emptive/post-surgery 4-day
regimen of oral ibuprofen 400 mg with that of lornoxicam
8 mg.
Methods Sixteen patients received ibuprofen or lornoxicam,
respectively, before and after surgery of impacted third molars
in two separate appointments, in a double-blind, randomized,
and crossover design. The postoperative analgesic and rescue
medication consumption was recorded and pain scores were
evaluated with a visual analogue scale at 2, 6, 24, 48, and 72 h,
postoperatively.
Results No statistically significant differences were found
between ibuprofen 400 mg and lornoxicam 8 mg with respect
to study medication (p=0.34) or rescue analgesic consump-
tion (p=0.5) (SUMstudy and SUMrescue). Ibuprofen:
SUMstudy median 7.5 interquartile range IQR (4.25–8),
95% CI (4.6–7.7); SUMrescue median and IQR 0, 95% CI
(−0.6–4.6). Lornoxicam: SUMstudy median 7 IQR (3.75–9),
95% CI (7.7–4.9); SUMrescue median and IQR 0, 95% CI
(−0.7–2.7). The area under the pain intensity curve (AUC2–72
PI) over the 4 days of investigation did not reveal significant
differences between the two medications (p=0.32). AUC2–72
PI ibuprofen: median 1,509.7 IQR (712.36–2,444.65); 95%
CI (1,078.7–2,156.5). AUC2–72 PI lornoxicam: median
1,166.9 IQR (783.4–2,221.2), 95% CI (1,032–2,130.6).
Moreover, patient satisfaction and incidence of adverse
events did not reveal any significant differences between
treatment groups.
Conclusion Ibuprofen 400 mg and lornoxicam 8 mg were
rated as equal and effective pain treatment medication after
wisdom tooth surgery. In comparison, neither of the drugs
provided clinical advantages nor did side effects occur more
frequently after one of the analgesics.
Keywords Lornoxicam . Ibuprofen . Postoperative dental
pain .Wisdom tooth extraction . Third molar surgery .
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Introduction
The removal of wisdom teeth is a common oral surgical
procedure, which causes an inflammatory process
expressed by the classical symptoms such as swelling,
pain, and impaired function. Postoperative pain following
surgical removal of mandibular third molars is a validated,
well-documented and highly sensitive model to assess
therapeutic relief of moderate to severe pain [1–3].
One of the drugs most frequently used in the third molar
model is ibuprofen, which is often used as a control
medication after oral surgery [4]. Ibuprofen, a propionic acid
derivate, has a clinical heritage of more than 45 years and its
safety profile has been studied extensively. It became the first
non-steroidal anti-inflammatory drug (NSAID) to be
approved for over-the-counter (OTC) use and compared to
other NSAIDs ibuprofen is associated with the lowest risk of
serious upper gastrointestinal complications [5,6].
Lornoxicam, a newer NSAID from the oxicam class, is
frequently used for the treatment of postoperative pain
following surgical interventions. Due to its rapid onset of
action and the short half-life (4–5 h), lornoxicam has a low
potential to evoke adverse reactions and has a good
gastrointestinal tolerability [7,8].
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The aim of this controlled, randomized, double-blind,
crossover pilot study was to compare the analgesic efficacy
and tolerability of a 4-day regimen of ibuprofen 400 mg
with that of lornoxicam 8 mg in 16 patients undergoing a
bilateral wisdom tooth extraction. Particularly it was of
interest which medication provides a stronger analgesic
effect, a longer duration of analgesia, and a better
tolerability.
Patients and methods
Subjects
After approval by the local ethics committee, males and
females aged between 18 and 40 years, weight between 40
and 100 kg, who were waiting for a surgical removal of
bilateral impacted third molars (as evaluated by panoramic
radiography), were identified from a waiting list at the
clinic. Twenty healthy patients with ASA class I or II
physical status were recruited. All subjects gave fully
informed written consent prior to entering the study.
Exclusion criteria included hypersensitivity to any
NSAID or aspirin, asthma, history of ulcus ventriculi or
duodeni, gastrointestinal hemorrhage, inflammatory gastro-
intestinal diseases, cardiac, renal, or hepatic insufficiency,
pregnancy, and any other clinically significant systemic
illness. Furthermore, any medication (except oral contra-
ception) within the previous 14 days disqualified patients to
enter the study.
Medication and blinding
Each subject had to undergo two surgical interventions to
bilaterally remove their third molars. The second surgery was
performed at least 3 weeks after the first intervention.
Ibuprofen (Brufen®; Abbott AG, Switzerland) and lornoxicam
(Xefo®; Nycomed PharmaAG, Switzerland) were used as pre-
emptive and postoperative medication. Ten subjects received
ibuprofen 400 mg before the first surgical intervention. The
alternative regimen administered before the second surgical
intervention was lornoxicam 8 mg. The remaining ten subjects
were treated vice versa. Both medications were administered
immediately before surgery and were applied for a total of
4 days if necessary. In case of pain recurrence, patients were
required to remedicate with the trial drug (up to three tablets
daily for each study medication). Paracetamol 500 mg
(Dafalgan®; Bristol-Myers Squibb SA, Switzerland) up to
eight tablets per day was supplied as rescue medication for
those patients who did not achieve adequate analgesia by use
of the study medication.
The allocation was randomized. Surgeon and patients
were blinded regarding the medication. Blinding was
conducted by the hospital pharmacy according to a list
generated after block randomization.
Surgery
Each surgery was performed under local anesthesia
employing 4% articaine hydrochloride with epinephrine
(adrenaline) 10 μg ml−1 (Ubistesin forte®; 3M AG,
Switzerland). Both surgical interventions were carried out
by the same surgeon according to a standardized technique
including mucosal flap, bone removal, splitting the tooth if
necessary, and using a cotton/iodine/vaseline drainage. If it
was considered necessary to remove an ipsilateral maxillary
or mandibular third molar, it was also removed in the same
procedure.
Study protocol
The study protocol was split into two parts; the clinical
record form and the patient record form. On the clinical
part, the investigator recorded demographic and surgical
data. These included age, weight, gender, types and number
of teeth extracted, mean duration of surgery, amount of
local anesthetic used, and the degree of difficulty of the
extraction. An assessment of the surgical trauma was made
and complications during surgery were charted by the
surgeon on a free text field.
The patient record form evaluated pain intensity (PI),
rescue and study medication consumption, and adverse
events.
Immediately after the surgical intervention, patients were
asked to assess their PI on the patient record form during
4 days. Postoperative pain scores were recorded on a
horizontal visual analogue scale (VAS) ranging from “no
pain” (0 mm=0%) on the left end to “unbearable pain”
(100 mm=100%) on the right end. Assessments were made
2 and 6 h postoperatively, and the first (24 h), second
(48 h), and third morning (72 h) after surgery at 10 o’clock.
The use of study and rescue medication was recorded by
the subjects on the form. The amount and the time of intake
were noted. Patients were asked to record details of any
adverse events they had experienced due to the study
medication.
Seven days after the surgical intervention, patients were
invited for a follow-up examination. The dressing and
sutures were removed. Patient satisfaction and a clinical
status were surveyed by the investigator on the clinical
record form. Parameters to assess patient satisfaction were
as follows: satisfaction with the surgical intervention,
satisfaction with the duration of the analgesic effect of the
trial drug, overall subjective assessment of pain relief, and
degree of recommendation of the respective medication.
These parameters were rated by the patients on a VAS
58 Oral Maxillofac Surg (2011) 15:57–62
ranging from “no satisfaction” (0 mm=0%) to “complete
satisfaction” (100 mm=100%).
Statistics
STATA software, version 10.1 (StataCorp, College Station,
TX 77845, USA) was used for data analysis. In the first
stage, possible carry-over or period effects were evaluated.
As primary efficacy parameters, the area under the pain
intensity curves (AUC2–72 PI) of the two medications and
the total amount of analgesic and rescue medication
consumption (SUMstudy/SUMrescue) over the 4 days of
observation were analyzed using ANOVA.
Medians, interquartile range (IQR) as well as maxima
and minima of the respective data distribution were
calculated. The 95% confidence interval of the mean was
calculated for the main end points.
Comparisons of the remaining distributions were made
by exact Wilcoxon test matched pairs statistics using the
Excel add-in Analyse-it (Analyse-It Software Ltd., Leeds,
UK). Statistically significant differences between data
distributions were considered at p values ≤0.05.
The pilot study design had been approved by a biostatis-
tician beforehand. A sample size for further studies was
calculated using nQueryAdvisor 6.0 (Statistical Solutions,
Saugus MA 01906, USA)
Results
Clinical parameters and patient characteristics
An overview of the demographic and surgical data obtained
is presented in Table 1.
Table 2 shows the features of the third molars extracted
in the study population.
Twenty patients entered the study as intent-to-treat
patients, but four were excluded from the trial due to an
extended delay of readmission for the second surgery.
Sixteen patients (11 male/five female) with a mean age
of 24.2 years, a mean weight of 65.8 kg, and a mean height
of 171.6 cm were included for the statistical analysis as per-
protocol population.
Neither a carry-over effect (AUC p=0.13, sum of
medication p=0.22) nor a period effect (AUC p=0.4, sum
of medication p=0.34) could be found comparing the two
treatment groups.
No significant inter-group differences were found accord-
ing to the degree of difficulty of surgery, duration of surgery,
amount of local anesthetic used, and the initial pain occurrence
(defined as interval from completion of surgery to second drug
administration of study medication) (Table 1).
In the lornoxicam group, three patients sustained
postoperative complications. Two patients suffered a mouth
antrum fistula and were treated with amoxicillin. One
patient developed a dry socket without pain.
In the ibuprofen treatment arm of the study, after two
surgical interventions postoperative complications were
observed. One subject had to be treated with a hemostatic
agent due to the lesion of a venous vessel during the
surgical procedure. The other one suffered a reversible
hypesthesia of the tongue after suspected compression of
the lingual nerve.
Pain intensity profiles after surgery
Table 3 summarizes the pain intensity profile over the 70-
h period following administration of ibuprofen and
lornoxicam.
Table 1 Patient demography and surgical characteristics—4-day regimen of ibuprofen 400 mg versus 4-day regimen of lornoxicam 8 mg;
crossover double-blinded pilot study in 16 patients undergoing third molar surgery
Lornoxicam Ibuprofen p value
Patient demography
Gender (male/female) 11/5
Age (years) 23.12 (21.61–26.06)
Height (cm) 171.5 (168.5–177.25)
Weight (kg) 65.8 (59.5–74.5)
Surgical characteristics
Injection (ml) 4.45 (2.45–5.1) 4.35 (2.45–5.1) n.s. (0.63)
Duration of surgery (min) 20 (15–31.75) 30 (17.25–36.25) n.s. (0.81)
Pain characteristics
Time until onset of pain after surgery (min) 215 (175–219.5) 250 (211–262.5) n.s. (0.7)
All values shown are expressed as median and interquartile range (first–third quartile) unless otherwise stated
n.s. no statistically significant inter-group differences; significant inter-group differences considered at p values ≤0.05
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The overall analgesic effect of ibuprofen was similar to
that of lornoxicam. No statistically significant inter-group
differences in pain intensity were found in the median AUC
values over the 4 days of investigation (AUC2–72 PI) as
shown in Table 4.
Study analgesic and rescue medication consumption
In terms of the amount of ingested study medication during the
4 days of observation (SUMstudy), there were no statistically
relevant differences between ibuprofen and lornoxicam.
In both treatment groups, three patients asked for rescue
medication. With regard to the amount of ingested rescue
medication over time (SUMrescue) and the number of
requesting patients, no significant differences between
ibuprofen and lornoxicam could be found (Table 4).
Tolerability
The patients rated the severity of all adverse effects as mild
to moderate. There was no significant difference between
the two treatments regarding the number and types of
adverse events reported. A total of two patients in the
ibuprofen group and two patients in the lornoxicam group
sustained adverse events.
A short-lasting nausea after drug administration was
recorded from one patient in the ibuprofen and two patients
in the lornoxicam group. One of these patients was treated
with amoxicillin concomitantly. However, it remains
unclear whether this nausea was due to the antibiotic or
due to lornoxicam.
One patient reported reversible heartburn symptoms after
administration of ibuprofen.
Patient satisfaction and overall assessment of the analgesic
efficacy 7 days after extraction
No statistically significant differences were found between
ibuprofen and lornoxicam concerning patient satisfaction
with the surgical intervention (p=0.6), satisfaction with the
duration of analgesic effect of the trial drug (p=0.7), and
the overall subjective assessment of pain relief over 7 days
(p=1.0). Furthermore, recommendation scores did not
reveal any significant differences (p=0.5).
When interviewing the patients 7 days after the second
intervention, seven patients out of 16 had the opinion that
ibuprofen was more effective than lornoxicam. Seven were
convinced that lornoxicam had a stronger effect and two
patients rated the effectiveness as equal.
Sample size calculation
This pilot study already allows to estimate a sample size
which is the minimum to achieve a power of 80%
Table 2 Surgeries performed in two study arms—4-day regimen of
ibuprofen 400 mg versus 4 day regimen of lornoxicam 8 mg;
crossover double-blinded pilot study in 16 patients undergoing third
molar surgery
Tooth number 18 28 38 48 28/38 18/48
Ibuprofen (no. of pat.) 2 3 3 0 4 4
Lornoxicam (no. of pat.) 2 3 0 3 4 4
Table 3 Pain intensity (PI) profile over a 70-h period of observation
after administration of a 4-day regimen ibuprofen 400 mg versus a 4-
day regimen lornoxicam 8 mg; crossover double-blinded pilot study in
16 patients undergoing third molar surgery; assessed on a 100 mm
VAS [0 mm=no pain (0%), 100 mm=unbearable pain (100%)]
2 h post-OP 6 h post-OP 1st morn post-OP 2nd morn post-OP 3rd morn post-OP AUC2–72 PI
PI ibuprofen
Max 40.4 48.5 56.5 51.9 50 3,194
75% Q 8.86 38.85 42.45 42.25 22.35 2,444.65
Median 3.3 18.3 26.2 22.95 5.9 1,509.7
25% Q 2.3 4.95 7 7.05 2.06 712.36
Min 0 2.3 3.3 0 0 163.05
PI lornoxicam
Max 45.7 54.2 50.4 76.1 51.4 3,604.2
75% Q 8.8 47.6 39.36 38.95 24.25 2,221.2
Median 6.6 28.25 16.85 15.9 17.6 1,166.9
25% Q 3.05 16.85 7.43 7.13 4.5 783.4
Min 0.4 3.3 0.47 0.47 0.47 94.4
Data are presented as median, first and third quartile, maximum and minimum
AUC2–72 PI area under pain intensity curve during the 4 days of observation (2–72 h after surgery)
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comparing the efficacy of the pain-relieving effect of both
drugs.
It is generally accepted that a pain score of 30% should
be the minimum target to be achieved in a situation of pain
by use of an analgesic medication. Therefore, this score was
used as the basis of calculation for a drug with a low but
still acceptable impact of analgesic action. As high impact,
the mean value of the best action of ibuprofen/lornoxicam
achieved in this study (around 0.4%) was chosen. Consid-
ering a power of 80%, nQuery Advisor software calculation
revealed a minimum number of six study participants to
confirm a difference between pain scores of the two drugs
at a required p value of 0.05.
Discussion
In the present pilot study, pain following surgical removal
of third molar teeth was used as a model to evaluate the
analgesic efficacy of ibuprofen compared to lornoxicam.
This pain model has been widely accepted to compare the
efficacy of drugs [1]. Third molar surgery for pain studies
fulfills most of the requirements of a good pain model: a
predictable development of inflammation, a homogenous
study population of young, healthy subjects who are able to
understand the given information, and surgery performed
without any concomitant medication. Furthermore, this type
of surgery is localized, performed with a standardized
technique, usually completed in 10 to 20 min, and
performed under local anesthesia. The age and general
health of the patients ensures a minimal risk of complica-
tions resulting from the administration of the study
medication [3]. In the present study, the two treatment
groups were well matched concerning duration of surgery,
amount of local anesthesia used, number of extracted
wisdom teeth, and amount of postoperative complications.
Neither of the study medication did show convincing
analgesic superiority when both drugs were given up to
three times daily for 4 days with respect to analgesic
efficacy, tolerability, and patient satisfaction.
Regarding the clinical efficacy parameters such as time
until initial pain occurrence, duration of the analgesia,
consumption of trial or rescue medication, ibuprofen and
lornoxicam did not reveal statistically significant differences.
Regarding patient satisfaction and the overall assessments
7 days postoperatively, the efficacy was rated as similar.
Eighty two percent in the ibuprofen group and 87% in the
lornoxicam group would recommend their medication.
Lornoxicam and ibuprofen were well tolerated and only
a few side effects were reported.
Considering the fact that pain scores of 30% and 0.4%
may serve as edge values for calculation of an AUC2–72
between the best and a still acceptable analgesic action of a
pain medication after wisdom tooth surgery, the sample size
in this pilot study sufficiently allows the statement that both
drugs tested may be rated as equally effective at the
respective dosage.
According to the pertinent literature, the efficacy of
lornoxicam has been shown for various surgical indications
[9–11] as well as dental surgery [8,12,13]. Furthermore, it
has been successfully used in the treatment of painful
inflammatory musculoskeletal conditions [14].
Some trials suggest that lornoxicam is as effective as the
opioid analgesics morphine, pethidine, and tramadol in
relieving postoperative pain [15].
When used after oral surgery, oral lornoxicam 8 mg was
as effective as oral ketorolac 10 mg [8], aspirin 650 mg
[13], and morphine 20 mg [12].
Nørholt and co-workers compared intramuscular injec-
tions of lornoxicam (4, 8, 16, and 20 mg) with morphine
(10 mg and 20 mg) and placebo in 252 patients with
moderate to severe pain. No significant difference was
detected between morphine 20 mg and lornoxicam 8, 16,
and 20 mg. However, lornoxicam was associated with a
significant lower incidence of adverse events than
morphine [12].
Table 4 Primary efficacy parameters: pain intensity (AUC2–72 PI) and
total analgesic/rescue medication consumption (SUMstudy/SUMrescue)
over the 4 days of observation—a 4-day regimen of ibuprofen
(Brufen®) 400 mg versus a 4-day regimen of lornoxicam (Xefo®)
8 mg; crossover double-blinded pilot study in 16 patients undergoing
third molar surgery; PI assessed on a 100 mm VAS [0 mm=no pain
(0%), 100 mm=unbearable pain (100%)]
Lornoxicam 95% CI lornoxicam Ibuprofen 95% CI ibuprofen p value
AUC2–72 PI 1,166.9 (783.4–2,221.2) 1,032–2,130.6 1,509.7 (712.36–2,444.65) 1,078.7–2,156.5 0.32
SUMstudy analgesia
(no. of tablets/4 days)
7 (3.75–9) 7.7–4.9 7.5 (4.25–8) 4.6–7.7 0.34
SUMrescue analgesia
(no. of tablets/4 days)
0 −0.7–2.7 0 −0.6–4.6 0.5
All values shown are expressed as median and interquartile range (first–third quartile). Statistically significant differences between data
distribution were considered at p values ≤0.05
95% CI 95% confidence interval of the mean
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A systematic review of studies that examined the relative
risks of gastrointestinal complications associated with differ-
ent NSAIDs found ibuprofen to be the least toxic, especially at
the lower end of the prescription dose range [16].
The Paracetamol, Aspirin and Ibuprofen New tolerability
(PAIN) study was a blinded, randomized study investigat-
ing the tolerability of ibuprofen, aspirin, and paracetamol at
OTC doses in the treatment of common types of acute pain
in a total of 8,677 adults randomized to either ibuprofen
(1,200 mg/day), paracetamol (3 g/day), or aspirin (3 g/day)
for 1–7 days. Ibuprofen was found to be of similar efficacy
compared to paracetamol (p=0.85). A total of 13.7%
patients reported adverse events (dyspepsia, abdominal)
after receiving ibuprofen. Both ibuprofen and paracetamol
were significantly better tolerated than aspirin (p=0.001)
[17].
Conclusion
Overall, equal analgesic effects can be achieved using pre-
emptive and post-surgical analgesic regimens of single doses
of ibuprofen 400 mg and lornoxicam 8 mg at a maximum of
three applications daily for 4 days after wisdom tooth surgery.
Both non-steroidal anti-inflammatory drugs proved to be
effective in the management of pain following surgical
removal of impacted third molar teeth with a high grade of
patient satisfaction.
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